Sulforadex

Evgen Pharma is a clinical-stage drug development company that utilizes its proprietary Sulforadex platform to stabilize sulforaphane, a naturally occurring compound with potent anti-cancer and anti-inflammatory properties. The company's lead asset, SFX-01, is a synthetic, stabilized version of sulforaphane that has been evaluated in Phase 2 clinical trials for indications including metastatic breast cancer and subarachnoid hemorrhage. By overcoming the inherent instability of natural sulforaphane, Evgen Pharma enables the therapeutic application of this compound across oncology and inflammatory diseases. The company focuses on modulating key signaling pathways such as Nrf2 and STAT3 to address high unmet medical needs.